GRT R918
Alternative Names: GRT-R918; Omicron variant COVID-2019 vaccine - Gritstone bio; Somicron-N-TCEXLatest Information Update: 19 Dec 2022
At a glance
- Originator Gritstone bio
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 13 Dec 2022 Gritstone bio has patent protection for antigen-encoding samRNA vectors and its applicability across candidates in oncology and infectious disease in USA
- 13 Dec 2021 Gritstone bio and University of the Witwatersrand plans a phase I trial for COVID-2019 infections (Prevention) in Africa in South Africa in Q2 2022
- 06 Dec 2021 Preclinical trials in COVID-2019 infections in USA (unspecified route) as of December 2021